anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is a sterile antimicrobial solution for topical ophthalmic use. It has pH of 4.0 to 6.2 and osmolality of 270 to 310 mOsm/kg.

Chemical Names: Trimethoprim sulfate, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine sulfate (2:1), is a white, odorless, crystalline powder with a molecular weight of 678.72 and the following structural formula:

Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formula are:

Contains: Actives: polymyxin B sulfate 10,000 units/mL; trimethoprim sulfate equivalent to trimethoprim 1 mg/mL. Preservative: benzalkonium chloride 0.04 mg/mL. Inactives: sodium chloride; sulfuric acid; and purified water. May also contain sodium hydroxide for pH adjustment.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic having remarkable actions of hydrolyzing the fat in fat cell into a fatty acid and glycerol and promoting the decomposition and combustion of the produced fatty acid and excellent in slimming effects by making the cosmetic include a specific amino acid and a pantetheine-related substance. SOLUTION: This cosmetic is obtained by including (A) one or more acidic amino acids and/or (B) one or more pantetheine-related substances. (C) One or more of caffeine, aminophylline, theophylline and xanthine and (D) carnitine are preferably further contained in the cosmetic. The amount of the formulated ingredient A is preferably 0.01-30%. When the ingredients B and D are formulated in the cosmetic, the respective amounts are preferably 0.01-30%. The amount of the formulated ingredient C is preferably 0.01-30%. The ingredient A is preferably a cysteine sulfinic acid/salt, a cysteine thiosulfonic acid/salt, etc.
The present invention provides a method of treating or preventing a disease in a subject, which disease is a liver injury induced by acetaminophen, comprising the step 5 of: administering an effective amount of a composition comprising at least 15% by weight of flavonoids obtained from leaves of at least one species of Vaccinium (V.) based on the weight of the composition to the subject. Fig. 1A Fig. 1B Lig. 1 &4 Fig 1 D Fig. IC Fig. ID
About 15 cases will receive oral tranexamic acid 500mg tablet once daily for three months. And will also be asked to apply a thin layer of topical HQ 4% cream on the hyperpigmented areas once every night.
Alglucosidase alfa is a hydrolytic lysosomal glycogen-specific enzyme encoded by the predominant of nine observed haplotypes of the human acid α-glucosidase (GAA) gene. Alglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of α-1,4- and α-1,6- glycosidic linkages of lysosomal glycogen.

Alglucosidase alfa is a glycoprotein with a calculated mass of 99,377 Daltons for the polypeptide chain, and a total mass of approximately 109,000 Daltons, including carbohydrates. Alglucosidase alfa has a specific activity of 3.6 to 5.4 units/mg (one unit is defined as that amount of activity that results in the hydrolysis of 1 micromole of synthetic substrate per minute under specified assay conditions). Alglucosidase alfa is intended for intravenous infusion. It is supplied as a sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with 10.3 mL Sterile Water for Injection, USP. Each 50 mg vial contains 52.5 mg alglucosidase alfa, 210 mg mannitol, 0.5 mg polysorbate 80, 9.9 mg sodium phosphate dibasic heptahydrate, and 31.2 mg sodium phosphate monobasic monohydrate. Following reconstitution as directed, each vial contains 10.5 mL reconstituted solution and a total extractable volume of 10 mL at 5 mg/mL alglucosidase alfa. Alglucosidase alfa does not contain preservatives; each vial is for single dose only.
PROBLEM TO BE SOLVED: To prepare a sustained release suppository of diclofenac sodium capable of manifesting an antiinflammatory and analgesic effect for a long period without causing a side reaction by setting the concentration in blood of the diclofenac sodium to a specific condition. SOLUTION: This sustained release suppository of diclofenac sodium enables the concentration in blood of the diclofenac sodium at 8hr after the time of the administration to be 1/3 to 2/3 of the maximum concentration in the blood by the administration of the suppository. The suppository having the condition is obtained by dispersing the diclofenac sodium powder in a base material made of an oil and fat or blending a water-soluble polymer or a surfactant. A triglyceride of a middle chain fatty acid, a triglyceride of saturated fatty acid (a hard fat), a triglyceride of a long chain fatty acid, etc., are preferable as the base material made of the oil and fat. A cellulosic polymer, an acrylic acid-based polymer, gelatin, agar, starch, etc., are preferable as the water-soluble polymer. Polyoxyethylene-cured castor oils, polysolvates, etc., are preferable as the surfactant. The suppository is mild in absorption and excretions and capable of maintaining the effective concentration for a long period.
Dolobid is a peripherally-acting analgesic agent with a long duration of action. Dolobid produces significant analgesia within 1 hour and maximum analgesia within 2 to 3 hours.

Consistent with its long half-life, clinical effects of Dolobid mirror its pharmacokinetic behavior, which is the basis for recommending a loading dose when instituting therapy. Patients treated with Dolobid, on the first dose, tend to have a slower onset of pain relief when compared with drugs achieving comparable peak effects. However, Dolobid produces longer lasting responses than the comparative agents.

Comparative single dose clinical studies have established the analgesic efficacy of Dolobid at various dose levels relative to other analgesics. Analgesic effect measurements were derived from hourly evaluations by patients during eight and twelve hour postdosing observation periods. The following information may serve as a guide for prescribing Dolobid.

Dolobid 500 mg was comparable in analgesic efficacy to aspirin 650 mg, acetaminophen 600 mg or 650 mg, and acetaminophen 650 mg with propoxyphene napsylate 100 mg. Patients treated with Dolobid had longer lasting responses than the patients treated with the comparative analgesics.

Dolobid 1,000 mg was comparable in analgesic efficacy to acetaminophen 600 mg with codeine 60 mg. Patients treated with Dolobid had longer lasting responses than the patients who received acetaminophen with codeine.

A loading dose of 1,000 mg provides faster onset of pain relief, shorter time to peak analgesic effect, and greater peak analgesic effect than an initial 500 mg dose.

In contrast to the comparative analgesics, a significantly greater proportion of patients treated with diflunisal did not remedicate and continued to have a good analgesic effect eight to twelve hours after dosing. Seventy-five percent (75%) of patients treated with Dolobid continued to have a good analgesic response at four hours. When patients having a good analgesic response at four hours were followed, 78% of these patients continued to have a good analgesic response at eight hours and 64% at twelve hours.
Patients with Cancer Receiving Myelosuppressive Chemotherapy

White blood cell counts of 100‚000/mm3 or greater were observed in approximately 2% of patients receiving NEUPOGEN at dosages above 5 mcg/kg/day. In patients with cancer receiving NEUPOGEN as an adjunct to myelosuppressive chemotherapy‚ to avoid the potential risks of excessive leukocytosis‚ it is recommended that NEUPOGEN therapy be discontinued if the ANC surpasses 10‚000/mm3 after the chemotherapy-induced ANC nadir has occurred. Monitor CBCs at least twice weekly during therapy. Dosages of NEUPOGEN that increase the ANC beyond 10‚000/mm3 may not result in any additional clinical benefit. In patients with cancer receiving myelosuppressive chemotherapy‚ discontinuation of NEUPOGEN therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days‚ with a return to pretreatment levels in 1 to 7 days.

Peripheral Blood Progenitor Cell Collection and Therapy

During the period of administration of NEUPOGEN for PBPC mobilization in patients with cancer, discontinue NEUPOGEN if the leukocyte count rises to > 100,000/mm3.
PURPOSE:To obtain an angiotensin I converting enzyme-inhibiting peptide reduced in side effects, its proper production and uses. CONSTITUTION:The angiotensin I converting enzyme-inhibiting peptide has a structure of the formula Gly-Lys-Lys-Val-Leu-Gln, Phe-Gln-Lys-Val-Val-Ala-X (X is Gly, Lys, Ser or a group free of amino acid residue). This peptide is produced by separating from swine erythrocyte and purifying the separated peptide. This peptide can be produced also by a chemical synthesis. The peptide can be applied to various kinds of foods and medicines. Since Gly-Lys-Lys-Val- Leu-Gln and Phe-Gln-Lys-Val-Val-Ala-X (X is Gly, Lys, or a group free of amino acid residue) exhibits angiotensin I converting enzyme-inhibiting action, the peptide lowers blood pressure.
It is Class I recommendation that STEMI require emergency revascularization with no delay. However, arrhythmias after acute myocardial infarction (AMI), particularly VAs, also occur in the early post-MI phase, leading to increased mortality. Previous studies have shown benefits of late reperfusion to electrical stability. The aim of this study was to investigate the association between different reperfusion timing and VAs to provide evidence for clinical decision-making for STEMI. In this multicenter, prospective, observational study, STEMI participants from July 2019 to December 2020 confirmed according to the 4th universal definition of myocardial infarction were enrolled, with a follow-up of 1, 6, 12 months, respectively. SO2RT was defined as the time interval between symptom onset and reperfusion timing which referred to the timing when coronary angiography showed Thrombolysis In Myocardial Infarction (TIMI) blood flow level 2\~3 immediately after percutaneous coronary intervention (PCI). The primary end point was VAs on 24h-dynamic electrocardiogram. Secondary outcomes included a composite of death from coronary heart disease, fetal of non-fetal ischemic stroke, revascularization, or chest pain requiring readmission.
Hepatic osteodystrophy, a prevalent manifestation of metabolic bone disease, can arise in the context of chronic liver disease. The THBS1-eNOS-NO signaling pathway plays a pivotal role in the maturation of osteoclast precursors. This study aimed to investigate the impact of Naltrexone (NTX) on bone loss by examining the THBS1-eNOS-NO signaling pathways in bile duct ligated (BDL) rats. Male Wistar rats were randomly divided into five groups (n = 10 per group): control, sham-operated + normal saline, BDL + normal saline, sham-operated + NTX (10 mg/kg), and BDL + NTX. Parameters related to liver injury were measured at the study's conclusion, and Masson-trichrome staining was employed to evaluate collagen deposition in liver tissue. Bone THBS-1 and endothelial nitric oxide synthase (eNOS) expression levels were measured using real-time PCR, while the level of bone nitric oxide (NO) was assessed through a colorimetric assay. NTX treatment significantly attenuated the BDL-induced increase in circulating levels of liver enzymes and bilirubin. THBS-1 expression levels, elevated after BDL, were significantly suppressed following NTX administration in the BDL + NTX group. Despite no alterations in eNOS expression between groups, the bone NO level, significantly decreased in the BDL group, was significantly reduced by NTX in the BDL + NTX group. This study partly provides insights into the possible molecular mechanisms in BDL-induced osteoporosis and highlights the modulating effect of NTX on these pathways. Further research is needed to establish the impact of NTX on histomorphometric indexes.
Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
Participants will be administered 35-40 placebo capsules orally with water. This will only occur once and takes approximately 30 minutes.
Corticosteroids are commonly used in children with bacterial meningitis; however, there are very few data regarding possible utility in neonates, particularly those born premature. We describe our experience using hydrocortisone in the treatment of a girl born at 26 weeks, 6 days gestation. She had suffered profound brain injury following late onset group B streptococcus sepsis and meningitis, and developed drug-resistant seizures. Because seizures continued despite treatment with phenobarbital, phenytoin, levetiracetam, lacosamide, and midazolam, intravenous hydrocortisone was added. We observed a marked decrease in focal electrographic seizures within 2 days of initiation of hydrocortisone. This experience suggests that corticosteroids could be a treatment option for drug-resistant seizures and status epilepticus in preterm neonates, particularly those with bacterial meningitis.
Fibrosis, driven by fibroblast activities, is an important contributor to morbidity and mortality in most chronic diseases. Endotrophin, a signaling molecule derived from processing of type VI collagen by highly activated fibroblasts, is involved in fibrotic tissue remodeling. Circulating levels of endotrophin have been associated with an increased risk of mortality in multiple chronic diseases. We conducted a systematic literature review collecting evidence from original papers published between 2012 and January 2023 that reported associations between circulating endotrophin (PROC6) and mortality. Cohorts with data available to the study authors were included in an Individual Patient Data (IPD) meta-analysis that evaluated the association of PROC6 with mortality (PROSPERO registration number: CRD42023340215) after adjustment for age, sex and BMI, where available. In the IPD meta-analysis including sixteen cohorts of patients with different non-communicable chronic diseases (NCCDs) (N = 15,205) the estimated summary hazard ratio for 3-years all-cause mortality was 2.10 (95 % CI 1.75-2.52) for a 2-fold increase in PROC6, with some heterogeneity observed between the studies (I2=70 %). This meta-analysis is the first study documenting that fibroblast activities, as quantified by circulating endotrophin, are independently associated with mortality across a broad range of NCCDs. This indicates that, irrespective of disease, interstitial tissue remodeling, and consequently fibroblast activities, has a central role in adverse clinical outcomes, and should be considered with urgency from drug developers as a target to treat.
The present invention is directed to erodible delivery devices and to the compositions comprising the devices. The devices comprise (a) a body formed of a bioerodible polymer or polymers together with a required excipient not generally considered to be a pore-former ("required excipient"), and (b) an active agent. The agent is released from the device at a controlled rate and in a therapeutically effective amount, with the rate being primarily independent of the erosion rate of the polymer. The rate of release of the active agent from the polymeric compositions of the present invention is significantly increased over the rate of release dependent on erosion of the polymer matrix. The invention makes possible the increased control over and improved reproducibility of the release profile of the agent from the polymer. The invention is further directed to a method of delivering to an environment of use an active agent, which method comprises placing an appropriately sized and shaped delivery device of the above description in the environment of use.
Low back pain is one of the reasons for applying to health institutions. Low back pain, which seriously affects patients' lives and leads to major financial losses, causes serious deficiencies in both developing and developed countries. Health professionals' perception of pain, factors associated with pain and fear avoidance attitudes of patients affect the success of treatment. The aim of this study is to determine the Turkish version, validity and reliability of ''Health Care Providers and Impairment Relationship Scale (HC-PAIRS)''. 165 physiotherapist working with chronic low back pain were included in the study. In order to determine the reliability of the scale, the intraclass correlation coefficient (ICC) will be used to determine the level of the relationship between the results of the first and second measurements. Cronbach's alpha coefficient will be used for homogeneity of the questions in the scale. For concurrent validity, correlation coefficient will be used to determine the agreement between the previously validated scales and the Turkish version of HC PAIRS.
Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
Self-efficacy is a cognitive-emotional factor that is consistently associated with behavioral change and, in particular, with changes in health behavior. Eating self-efficacy, understood as adopting and maintaining behaviors such as controlling one's weight and trusting in one's ability to control one's eating behavior, has been proposed for managing obesity. This study aimed to validate the Chilean version of the Weight Efficacy Lifestyle Questionnaire (WEL) in a sample of adults from the general population. Four hundred sixty-nine individuals (69.08% women, mean age = 38.02; SD = 10.31) participated in the study. An instrumental design was used geared toward developing tests and psychometric instruments, including adapting existing ones. Exploratory and confirmatory factor analyses were performed. The instrument version validated in Spain was applied in the study. The analysis obtained an instrument of 11 items with adequate psychometric properties allowing its use in clinical and research settings. It can help assess eating self-efficacy in the general population.
The present invention relates to a Chinese traditional medicine combination for treating neurodermatitis. The medicine uses more than ten Chinese herbal medicines as raw materials such as pagodatree flower, Clematis chinensis, Caulis Spatholobi and Herba Artemisia Capillaris. The medicine has efficacy of activating blood, arresting blood, removing wind and dissipating hard mass. The present invention is developed by combination with modern scientific research achievements on the basis of the traditional Chinese traditional differentiation treatment. The invention is to provide a Chinese traditional medicine combination for treating neurodermatitis. The medicine is characterized in exact curative effect, safety, convenience, no toxic and side effects and low price.
Patients who were previously implanted with the LINX device during repair of a hiatal hernia \>3 cm \>2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at 3 and 5 years to determine recurrence of hiatal hernia.
The efficacy of aliskiren was evaluated in an 8-week randomized, double-blind trial in 267 pediatric patients with hypertension 6 years to 17 years of age (Study CSPP100A2365; NCT01150357). The majority of patients (82%) had primary hypertension, 59% had a BMI ≥95th percentile, 20% had an estimated GFR between 60 and 90 mL/min/1.73m2 and < 2% had an estimated GFR < 60 mL/min/1.73m2. The mean age was 11.8 years and 74% of patients were Caucasian. In the initial 4-week,dose-response phase of the trial patients were randomized to weight-based low, mid and high dosing groups. At the end of this phase, patients entered a 4-week randomized withdrawal phase in which they were re-randomized in each weight category in a 1:1 ratio to continue the same dose of aliskiren or take placebo. 

During the initial dose-response phase, aliskiren reduced both systolic and diastolic blood pressure in a weight-based dose-dependent manner. Sitting systolic blood pressure, the trial’s primary endpoint, was reduced by 4.8, 5.6 and 8.7 mmHg from baseline in the low, medium and high dose groups, respectively. In the randomized withdrawal phase, the mean difference between the high dose group of aliskiren and placebo in the mean change in sitting systolic blood pressure was ­ 2.7 mmHg.  


Following the 8-week trial, 208 patients were enrolled in a 52-week extension trial in which patients were randomized in a 1:1 ratio (irrespective of whether they were on placebo or aliskiren at the end of the 8-week study) to receive either aliskiren or enalapril (CSPP100A2365E1; NCT01151410). The extension study included 3 dose levels based on weight; optional dose up-titrations were allowed during the study to control blood pressure.  


At the end of 52 weeks, reductions in blood pressure from baseline were similar in patients receiving aliskiren (7.6/3.9 mmHg) and enalapril (7.9/4.9 mmHg).
Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
This study is composed of three dosing plan stages. The initial stage of this trial is the dose-escalation stage. A modified dose-escalation 3+3 design will be utilized to identify a safe maximum tolerated dose (MTD) of STI-6129 in patients with relapsed or refractory systemic AL amyloidosis. After identification of the MTD, or the finding that the last dosing cohort is tolerated well (i.e., the maximum practical dose \[MPD\]), 12 patients will be enrolled to receive STI-6129 treatment at the MTD/MPD level to collect pharmacokinetic data ( the pharmacokinetic (PK) stage) to model a treatment schedule that achieves a stable effective serum concentration. Results from the dose-escalation stage and the pharmacokinetic stage will be analyzed to develop a treatment dose/schedule for treating 30 additional patients enrolled in the expansion stage.

Each patient enrolled will receive up to three 4-week cycles of STI-6129, unless a longer intermission is required. After the treatment period, patients will be monitored for up to a year.
PROBLEM TO BE SOLVED: To obtain an effective photochemotherapeutic agent, capable of manifesting pharmacodynamic effects when excited by irradiation of ultraviolet rays after administration to a living body and having high safety. SOLUTION: This photochemotherapeutic agent comprises guanidinovaleric acid represented by the formula or its salt as an active ingredient. The guanidinovaleric acid represented by the formula or its salt is activated when irradiated with ultraviolet rays to acts as an anticancer agent capable of manifesting killing activities against cancer cells and useful as the effective photochemotherapeutic agent capable of acting as a therapeutic agent for dermatopathy capable of manifesting suppressing activities against inflammations of the skin. The guanidinovaleric acid is obtained by culturing a microorganism, belonging to the genus Streptomyces and capable of producing the guanidinovaleric acid (Streptomyces sp. MJ859-CF4) and collecting the guanidinovaleric acid from the resultant cultured product.  The dose thereof is 0.1-500 mg expressed in terms of the guanidinovaleric acid in the case of parenteral administration and 0.1mg to 2.5g in the case of oral administration.